Header Logo

Connection

Lynn Morris to Nevirapine

This is a "connection" page, showing publications Lynn Morris has written about Nevirapine.
Connection Strength

1,281
  1. Development of phenotypic HIV-1 drug resistance after exposure to single-dose nevirapine. J Acquir Immune Defic Syndr. 2008 Dec 15; 49(5):538-43.
    View in: PubMed
    Score: 0,297
  2. Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission. AIDS. 2006 Apr 24; 20(7):995-1002.
    View in: PubMed
    Score: 0,248
  3. Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial. Lancet Infect Dis. 2012 Jul; 12(7):521-30.
    View in: PubMed
    Score: 0,093
  4. HIV-1 drug resistance at antiretroviral treatment initiation in children previously exposed to single-dose nevirapine. AIDS. 2011 Jul 31; 25(12):1461-9.
    View in: PubMed
    Score: 0,089
  5. Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial. JAMA. 2010 Sep 08; 304(10):1082-90.
    View in: PubMed
    Score: 0,084
  6. Women exposed to single-dose nevirapine in successive pregnancies: effectiveness and nonnucleoside reverse transcriptase inhibitor resistance. AIDS. 2009 Apr 27; 23(7):809-16.
    View in: PubMed
    Score: 0,076
  7. Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy. Clin Infect Dis. 2009 Feb 15; 48(4):462-72.
    View in: PubMed
    Score: 0,075
  8. Transmission rates in consecutive pregnancies exposed to single-dose nevirapine in Soweto, South Africa and Abidjan, Côte d'Ivoire. J Acquir Immune Defic Syndr. 2007 Jun 01; 45(2):206-9.
    View in: PubMed
    Score: 0,067
  9. Selection and persistence of viral resistance in HIV-infected children after exposure to single-dose nevirapine. J Acquir Immune Defic Syndr. 2007 Feb 01; 44(2):148-53.
    View in: PubMed
    Score: 0,065
  10. Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J Infect Dis. 2005 Jul 01; 192(1):16-23.
    View in: PubMed
    Score: 0,058
  11. Low frequency of the V106M mutation among HIV-1 subtype C-infected pregnant women exposed to nevirapine. AIDS. 2003 Jul 25; 17(11):1698-700.
    View in: PubMed
    Score: 0,051
  12. Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa. AIDS Res Hum Retroviruses. 2011 Sep; 27(9):945-56.
    View in: PubMed
    Score: 0,022
  13. Detection of low-level K65R variants in nucleoside reverse transcriptase inhibitor-naive chronic and acute HIV-1 subtype C infections. J Infect Dis. 2011 Mar 15; 203(6):798-802.
    View in: PubMed
    Score: 0,021
  14. Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants. AIDS. 2008 Jul 11; 22(11):1333-43.
    View in: PubMed
    Score: 0,018
  15. A model of directional selection applied to the evolution of drug resistance in HIV-1. Mol Biol Evol. 2007 Apr; 24(4):1025-31.
    View in: PubMed
    Score: 0,016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.